Showing results (11-20 of 60) with videos related to

Sort By:
Pageof 6
Methods in Molecular Biology (Clifton, N.J.)|March 6, 2003
Manipulating expression of endogenous oncogenic proteins using an antisense oligonucleotide approach in prostate cancer cellsDaqing Wu, Ginger G Wescott, David M Terrian
Anticancer Research|October 25, 2017
Mifepristone Has Limited Activity to Enhance the <i>In Vivo</i> Efficacy of Docetaxel and Enzalutamide Against Bone Metastatic and Castration-Resistant Prostate CancerYang Yang, Xin Li, Kenza Mamouni, et al.
Anticancer Research|October 28, 2020
<i>In Vitro</i> Effect and Mechanism of Action of Ergot Alkaloid Dihydroergocristine in Chemoresistant Prostate Cancer CellsLijuan Bai, Xin Li, Xiaowei Ma, et al.
Medicine|July 1, 2022
Plasma neurofilament light chain: A biomarker predicting severity in patients with acute ischemic strokeJixia Wu, Daqing Wu, Youbao Liang, et al.
Bio-Protocol|December 15, 2021
Measurement of Bone Metastatic Tumor Growth by a Tibial Tumorigenesis AssayBaotong Zhang, Xin Li, Wei-Ping Qian, et al.
Scientific Reports|July 27, 2016
Co-targeting EGFR and survivin with a bivalent aptamer-dual siRNA chimera effectively suppresses prostate cancerHong Yan Liu, Xiaolin Yu, Haitao Liu, et al.
Molecular Pharmaceutics|October 10, 2024
Targeted Delivery of AR-V7 siRNA with Bivalent PSMA Aptamers Effectively Suppresses the Growth of Enzalutamide-Resistant Prostate CancerLu Xue, Xiaolin Yu, Lijing Zhao, et al.
Pharmaceutics|December 28, 2021
Non-Cationic RGD-Containing Protein Nanocarrier for Tumor-Targeted siRNA DeliveryXiaolin Yu, Lu Xue, Jing Zhao, et al.
Pharmaceutics|November 27, 2025
Correction: Yu et al. Non-Cationic RGD-Containing Protein Nanocarrier for Tumor-Targeted siRNA Delivery. <i>Pharmaceutics</i> 2021, <i>13</i>, 2182Xiaolin Yu, Lu Xue, Jing Zhao, et al.
ACS Applied Materials & Interfaces|April 5, 2013
Quantum dot-based, quantitative, and multiplexed assay for tissue stainingHong Xu, Jing Xu, Xu Wang, et al.
Pageof 6